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COPD is not as straightforward a disease as we
once thought is was. Thank goodness! For if the FEV1
were simply the be-all and end-all of COPD assess-
ment, then most of our therapeutic interventions
would be for naught. Fortunately, clinicians treating
patients with this disease have reason for guarded
optimism. This is reflected in the latest ATS-ERS
COPD guidelines, which view it as a p`reventable
and treatable disease,' 1 emphasizing those aspects
of disease modification which are achievable. And
the majority of patients can have clinically mean-
ingful improvement with comprehensive therapy.
Our responsibility is to provide this therapy to our
patients.
The accompanying four reviews are the result of
the two-day conference, “Thinking Outside the Box:
New Views on the Diagnosis, Staging, and Manage-
ment of COPD”, which was held in Stresa, Italy in
September 2006, and attended by 28 leading inter-
national experts in the field. This was a multidisci-
plinary endeavour. The charge given to the invited
faculty was to briefly present the newest concepts
in the assessment and management of this disease,
and then open up the floor to a lengthy and wide-
ranging discussion in which all experts interacted.
Targeting the COPD exacerbation was chosen as
the first review, since exacerbation profoundly af-
fects the quality and quantity of life, the progres-
sion of lung dysfunction, and the cost of care in
COPD patients. The ERS and ATS define acute exac-
erbation of COPD as “an event in the natural course
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of the disease characterized by a change in the pa-
tient' s baseline dyspnea, cough, and/or sputum be-
yond the day-to-day variability sufficient to warrant
a change in management.”1 The pervasive nature of
its systemic effects is now appreciated. We have to
think beyond simple maintenance therapy of COPD:
good medical care must also include exacerbation
prevention and management strategies. Both phar-
macologic and non-pharmacologic interventions can
substantially reduce the frequency of exacerba-
tions, and should be used together for optimal ef-
fect. Furthermore, the early treatment of the ex-
acerbation through collaborative self-management
education really works.
Developing concepts in the pulmonary rehabili-
tation of COPD gives rightful priority to the role
of pulmonary rehabilitation in the management of
COPD.2 The latest evidence shows that COPD is a
partially reversible disease if patients receive ap-
propriate therapy. The reversibility relates to symp-
toms, exercise capacity and quality of life, in which
pulmonary rehabilitation plays a fundamental role.
In general, pulmonary rehabilitation produces the
greatest improvements in dyspnea, exercise capac-
ity, and quality of life of any therapy out there for
COPD. It should be viewed as complementary to
otherwise standard therapy: 1) After maximal im-
provement is gained from pharmacologic therapy,
most patients will still have improvements in dys-
pnea, exercise capacity and quality of life when it
is added; 2) Optimization of pharmacologic man-
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agement, in turn, allows for greater gains from the
exercise training component of pulmonary rehabil-
itation. This is a good marriage. This review dis-
cusses ways we can improve pulmonary rehabilita-
tion, ranging from the “Row Your Own Boat” pro-
gram (peer-to-peer education aimed at getting the
patient to take ownership of his/her own health sta-
tus) to approaches that optimize exercise training,
to the science (or lack of it) behind ambulatory sup-
plemental oxygen use.
Predictors of Survival in COPD: More than Just
the FEV1emphasizes the prognostic importance of
variables other than the FEV1. COPD clearly has sys-
temic consequences, and it should not be surprising
that variables that better reflect the overall p`roto-
plasm' of the individual are better at predicting sur-
vival. Thus, the six minute walk distance, exercise
capacity, level of dyspnea, functional status, and
body composition all are important factors in prog-
nosis. This provides the rationale for the multidi-
mensional staging of COPD, which is coming of age.
It' s about time --- Directing our Attention toward
Modifying the Course of COPD deals with the impor-
tant objectives modifying the downhill trajectory of
this disease. COPD is associated with high morbid-
ity, mortality, and cost, but it can be successfully
managed and the costs can be reduced by an effec-
tive follow-up. The concept of favorably modifying
the course of COPD can mean different things. Most
clinicians would prominently list a reduction in the
rate of decline in lung function and prolonged sur-
vival in this category. To date, only smoking cessa-
tion intervention, administration of long-term oxy-
gen therapy to hypoxemic patients and (in highly-
selected individuals) lung volume reduction surgery
have had limited success in these areas. Pharma-
ceutical agents or combinations may eventually be
unequivocally demonstrated to have effectiveness
too. However, if your concept of disease modifica-
tion is broader - and encompasses decreases in ex-
acerbation frequency, exercise capacity and func-
tional status --- then we are making real progress.
Thinking Outside the Box naturally leads us to fo-
cus on those aspects of the COPD disablement pro-
cess that are treatable and to continue working on
those areas that need further research. In the man-
agement of COPD, we are now more inclined to view
the glass as half-full.
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